Novel vaccine development firm Agilvax seeks $2 million to fund animal tests
Vaccines are one of the most cost-effective ways to treat diseases, believes Joe Shaw CEO of St. Paul, Minnesota-based startup Agilvax. But current technologies — and even some emerging ones — are lacking in various ways in that they take too long to develop and may not be highly immunogenic. Agilvax is attempting to change […]